Back to results
US 2011/0301149 A1Published application
Compositions and methods for treating alcohol use disorders, pain and other diseases
AssigneeVm Discovery Inc.
InventorJay Jie-Qiang Wu
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds which antagonize epsilon protein kinase C (PKCε). These compounds have a structural formula (Ia), (Ic) or (II). The present invention also provides pharmaceutical compositions containing these compounds and methods of treating various diseases, conditions, and/or symptoms by using these compounds.
Claims26
A compound having a structural formula (Ia):
- or a salt, solvate, or physiologically functional derivative thereof,
- wherein:
- X and Y are independently CR1R5, NR1, O or S, provided that at least one of X and Y is CR1R5 or NR1;
- Z1 and Z2 are independently CHR2, NR2, O, or S;
- A1, A2, A3, and A4 are independently CR3 or N;
- each R1, R2, R3, and R5 is independently hydrogen, halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, —C(O)NR7R8, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl;
- R7 and R8 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl, or alternatively, R7 and R8, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloheteroalkyl ring;
- with the following provisos:
- (a) at least one of Z1 and Z2 is CHR2 or NR2;
- (b) at least one of A1, A2, A3, and A4 is CR3;
- (c) at least one of R1, R2, R3 and R5 is not hydrogen;
- (d) when R1 and R5 are independently hydrogen, aryl or substituted aryl;
- R2 is hydrogen, arylalkyl or substituted arylalkyl;
- then R3 is not aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- (e) when R3 is —C(O)NR7R8;
- R2 is hydrogen or substituted arylalkyl;
- then at least one of R1 and R5 is not halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, alkyl, or substituted alkyl;
- and
- (f) when R3 is —C(O)NR7R8;
- R7 is hydrogen;
- R8 is substituted alkyl, arylalkyl, substituted arylalkyl, heteroaryl, heteroalkyl or substituted aryl;
- R2 is hydrogen or substituted arylalkyl;
- then at least one R1 is not halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, alkyl, or substituted alkyl.
20 more elements
A compound having a structural formula (II),
- or a salt, solvate, or physiologically functional derivative thereof,
- wherein:
- A is N or CH;
- B is a 5-, 6-, or 7-membered cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl ring;
- D is NR4, S, or O;
- R1, R2, R3, and R4 are independently hydrogen, halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, —C(O)NR5R6, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl;
- R5 and R6 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl, or alternatively, R5 and R6, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloheteroalkyl ring;
- and
- X is —CH2—, CH2—O—, —CH2—S—, —O— or —S—.
6 more elements
22-24. (canceled)
(canceled)
Dependencies are inferred from the claim text.